Clinical Trials Logo

Clinical Trial Summary

Since the early 1990s, evidence-based medicine has played an increasingly important role in decision-making for the treatment of patients with cancer. The highest level of evidence is attributed to the results of randomized comparative studies, and the public health authorities require proof from randomized therapeutic trials before authorizing the use of new treatments. Patients included in therapeutic trials benefit either from the best current treatment (control group) or from a treatment supposed to present a better or similar efficacy, together with an extremely rigorous surveillance protocol. Inclusion in a randomized therapeutic trial represents the optimal therapeutic strategy.In order to optimize the fight against cancer, French public health policies have led to the progressive implementation of successive nationwide "Cancer Plans" since 2003. One of the objectives is to increase the proportion of patients included in clinical research trials. Thus, the fraction enrolled in France has progressively increased but remained low at around 8% in 2010. The current 2014-2019 plan aims to expand inclusion to 50,000 patients per year. In a context of socio-economic inequalities that concern resources, residence and access to services, identifying factors that determine inclusion in trials will in turn highlight the reasons for non-inclusion.

The aim of this study was to determine, at a population level, the influence of demographic characteristics and socio-economic status of patients with digestive cancer on inclusion in a clinical trial.

Between 2004 and 2010, 4632 patients were recorded by the Burgundy Digestive Cancer Registry. According to a balancing score, the 136 patients included in a clinical trial were matched with 272 patients who met the eligibility criteria for trials. Deprivation was measured by the ecological European deprivation index. A conditional multivariate logistic regression was performed.

Clinical Trial Description


Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

NCT number NCT02894775
Study type Observational
Source Centre Hospitalier Universitaire Dijon
Status Completed
Phase N/A
Start date January 2013

See also
  Status Clinical Trial Phase
Recruiting NCT02386397 - Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer Phase 1/Phase 2
Recruiting NCT03294252 - Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers Phase 1/Phase 2
Completed NCT02169908 - Analysis of Chronic Neuropathic Pain Markers in Patients Treated With Oxaliplatin N/A
Completed NCT02797197 - Feasibility of Systematic Handgrip Strength (HGS) Testing and Short-term Changes in Muscle Strength in Digestive Cancer Patients Treated by Chemotherapy N/A
Recruiting NCT03449264 - Development of Clinical and Biological Database N/A
Not yet recruiting NCT03670199 - Improving the Quality of Life of Cancer Patients Through a Perioperative and Coordinated Nutrition and Physical Care Program. N/A
Withdrawn NCT01763489 - ASSIST Tool and Surgical Randomized Controlled Trial Applicability N/A
Recruiting NCT02387138 - A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan Phase 1
Not yet recruiting NCT03460197 - Comparison Between Two Tissue Acquisition Techniques by Endoscopic Ultrasound. (EUS) N/A